Prostatype Genomics
Prostatype Genomics' Newsletter: Update on Medicare application and publication of U.S. study results
This issue updates on the company's Medicare application in the U.S., upcoming publication of results from the completed U.S. validation study and the opportunity to watch a filmed company presentation with more information about the complementary opportunities based on the Prostatype® platform that were recently presented.
Content of the newsletter:
- Update on the company’s Medicare process and the U.S.
- U.S. Validation study by Veterans Affairs submitted for publication
- Update on billing of private insurance companies in the U.S.
- Completed investments in the U.S. puts Prostatype Genomics in a strong position
- New commercial opportunities unlocked through earlier R&D investments
- Prostatype Genomics raised SEK 11.5 million through TO5 warrant exercise
Read the full newsletter and subscribe via this link:
https://www.ii.se/en/prostatype-genomics-newsletter-november-2025/
For more information, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: fredrik.rickman@prostatypegenomics.com
Certified Adviser
Tapper Partners AB
Telephone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
| Datum | 2025-11-25, kl 14:30 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!